Cat. No.: DAB-0012737
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human PLSCR1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PLSCR1 |
| UniProt No. | O15162 |
| Gene ID | 5359 |
| Gene Description | Phospholipid scramblase 1 is 1 of 4 scramblases encoded in the human genome. Phospholipid scramblases function to catalyze calcium-mediated ATP-independent mobilization of phospholipids between the inner and outer leaflet of plasma membrane in activated, injured, or apoptotic cells. PLSCR1 is a type-II transmembrane protein with a short 9 amino acid C-terminal domain and a long N-terminal extracellular domain. Although PLSCR1 is part of a family of proteins that function to catalyze phospholipid mobilization, PLSCR1 may have alternative functions. Rather, PLSCR1 may function to activate cell signaling pathways, particularly in phagocytic cells of monocyte/macrophage lineage. Microglia, resident macrophages of the brain, play a key role in clearance of cellular and pathologic debris where altered phagocytosis may contribute to neurodegenerative diseases like Alzheimer’s disease. PLSCR1 may regulate microglia phagocytosis, representing a potential therapeutic target to modulate microglia phagocytosis. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
